Literature DB >> 18239290

Adrenergic beta1 receptor polymorphism (Ser49Gly) is associated with obesity in type II diabetic patients.

Shinpei Nonen1, Isamu Yamamoto, Jianmin Liu, Makiko Maeda, Takashi Motomura, Tsuyoshi Igarashi, Yasushi Fujio, Junichi Azuma.   

Abstract

In the process of lipolysis, adipocytes are stimulated by catecholamines through beta(1), beta(2), and beta(3) adrenergic receptors (ARs). So far, beta(2) and beta(3) AR polymorphisms have been reported related to obesity. However, the relation of beta(1)AR polymorphisms to obesity has not been evaluated. In the present study, we examined whether betaAR polymorphisms are associated with obesity-related phenotype in type II diabetic patients. Polymorphisms of beta(1)Ser49Gly, beta(1)Arg389Gly, beta(2)Arg16Gly, beta(2)Gln27Glu and beta(3)Trp64Arg were genotyped in 188 type II diabetic patients by PCR-RFLP. Among these polymorphisms, beta(1)Ser49Gly was found to be associated with obesity. Subjects with beta(1)Gly49 allele showed higher body mass index (BMI) than those with Ser49/Ser49 genotype (24.7+/-3.7 vs. 23.4+/-3.3 kg/m(2); p=0.031). Subjects with beta(1)Gly49 allele were more frequently overweight (BMI >or= 25 kg/m(2)) compared with beta(1)Ser49 homozygous group (42.1 vs. 24.4%, p=0.015). By multiple linear regression analysis, beta(1)Ser49Gly polymorphism was independently associated with higher BMI (p=0.019, beta=0.166). Our data indicate that the Gly49 allele in beta(1)AR is associated with higher BMI in type II diabetic patients. Genotyping for beta(1)Ser49Gly polymorphism in type II diabetic patients may have clinical benefit to predict obesity, thereby contributing to the prevention of insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18239290     DOI: 10.1248/bpb.31.295

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

1.  Interaction of Neighborhood and Genetic Risk on Waist Circumference in African-American Adults: A Longitudinal Study.

Authors:  Tyler McDaniel; Dawn K Wilson; M Sandra Coulon; Allison M Sweeney; M Lee Van Horn
Journal:  Ann Behav Med       Date:  2021-07-22

2.  ADRB3 polymorphism rs4994 (Trp64Arg) associates significantly with bodyweight elevation and dyslipidaemias in Saudis but not rs1801253 (Arg389Gly) polymorphism in ARDB1.

Authors:  Maha Daghestani; Mazin Daghestani; Mamoon Daghistani; Abdelmoneim Eldali; Zeinab K Hassan; Maha H Elamin; Arjumand Warsy
Journal:  Lipids Health Dis       Date:  2018-03-27       Impact factor: 3.876

Review 3.  Pharmacogenomics of Medication-Induced Weight Gain and Antiobesity Medications.

Authors:  Sneha Singh; Maria L Ricardo-Silgado; Suzette J Bielinski; Andres Acosta
Journal:  Obesity (Silver Spring)       Date:  2021-02       Impact factor: 5.002

4.  Relationships of adrenoceptor polymorphisms with obesity.

Authors:  Kazuko Masuo; Gavin W Lambert
Journal:  J Obes       Date:  2011-04-04

5.  Beta 1, Beta 2 and Beta 3 Adrenergic Receptor Gene Polymorphisms in a Southeastern European Population.

Authors:  Martha-Spyridoula Katsarou; Aikaterini Karathanasopoulou; Angeliki Andrianopoulou; Vasileios Desiniotis; Efthymios Tzinis; Efthimios Dimitrakis; Maria Lagiou; Evangelia Charmandari; Michael Aschner; Aristeidis M Tsatsakis; George P Chrousos; Nikolaos Drakoulis
Journal:  Front Genet       Date:  2018-11-28       Impact factor: 4.599

6.  Vitamin D Supplementation and Genetic Polymorphisms Impact on Weight Loss Diet Outcomes in Caucasians: A Randomized Double-Blind Placebo-Controlled Clinical Study.

Authors:  Konstantinos Xenos; Maria Papasavva; Athanasios Raptis; Martha-Spyridoula Katsarou; Nikolaos Drakoulis
Journal:  Front Med (Lausanne)       Date:  2022-03-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.